Eiger Biopharmaceuticals’ (EIGR) “Buy” Rating Reaffirmed at Wedbush

Share on StockTwits

Eiger Biopharmaceuticals (NASDAQ:EIGR)‘s stock had its “buy” rating reissued by equities researchers at Wedbush in a report released on Tuesday. They currently have a $43.00 target price on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 226.25% from the company’s previous close.

EIGR has been the subject of a number of other research reports. BidaskClub raised shares of Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 22nd. ValuEngine cut shares of Eiger Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, December 17th. Robert W. Baird began coverage on shares of Eiger Biopharmaceuticals in a report on Monday, January 28th. They issued an “outperform” rating and a $47.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Tuesday, February 5th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $31.88.

Shares of EIGR stock traded down $0.10 on Tuesday, reaching $13.18. The company had a trading volume of 41,200 shares, compared to its average volume of 111,976. The stock has a market capitalization of $251.22 million, a P/E ratio of -2.71 and a beta of 1.67. The company has a current ratio of 4.59, a quick ratio of 4.59 and a debt-to-equity ratio of 0.56. Eiger Biopharmaceuticals has a one year low of $8.20 and a one year high of $18.00.

In other Eiger Biopharmaceuticals news, Director Thomas John Dietz acquired 5,000 shares of the company’s stock in a transaction that occurred on Thursday, December 20th. The stock was acquired at an average price of $9.98 per share, for a total transaction of $49,900.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at $99,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Eldon C. Mayer III bought 7,500 shares of the firm’s stock in a transaction on Monday, November 26th. The shares were purchased at an average cost of $9.75 per share, with a total value of $73,125.00. Following the transaction, the director now directly owns 7,500 shares in the company, valued at approximately $73,125. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 23,727 shares of company stock valued at $242,953. 7.90% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in EIGR. Jane Street Group LLC acquired a new stake in Eiger Biopharmaceuticals during the 4th quarter valued at approximately $114,000. Dimensional Fund Advisors LP acquired a new stake in Eiger Biopharmaceuticals during the 3rd quarter valued at approximately $194,000. Tocqueville Asset Management L.P. acquired a new stake in Eiger Biopharmaceuticals during the 3rd quarter valued at approximately $203,000. Bank of New York Mellon Corp increased its position in Eiger Biopharmaceuticals by 36.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 20,412 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 5,492 shares during the period. Finally, Millennium Management LLC acquired a new stake in Eiger Biopharmaceuticals during the 4th quarter valued at approximately $255,000. 50.65% of the stock is owned by institutional investors and hedge funds.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Recommended Story: Coverage Ratio

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply